(VIANEWS) - USA Truck (USAK), Tivity Health (TVTY), Supernus Pharmaceuticals (SUPN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. USA Truck (USAK)
15.2% sales growth and 25.26% return on equity
USA Truck, Inc. is a truckload carrier that operates in Canada, Mexico, the United States.
USA Truck's sales growth this year is anticipated to be 10.9% and 1.6% for next year.
Year-on-year quarterly revenue growth grew by 26.4%, now sitting on 710.39M for the twelve trailing months.
Volume
Today's last reported volume for USA Truck is 428328 which is 147.82% above its average volume of 172836.
USA Truck's sales growth for the next quarter is 15.2%. The company's growth estimates for the ongoing quarter and the next is 79.1% and 60%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.26%.
Volatility
USA Truck's last day, last week, and last month's current intraday variation average was 6.54%, 6.63%, and 3.98%, respectively.
USA Truck's highest amplitude of average volatility was 7.88% (day), 8.47% (last week), and 5.86% (last month), respectively.
USA Truck's Stock Yearly Top and Bottom Value
USA Truck's stock is valued at $16.06 at 11:22 EST, way under its 52-week high of $29.09 and way higher than its 52-week low of $13.01.
USA Truck's Moving Average
USA Truck's value is way below its 50-day moving average of $22.25 and way below its 200-day moving average of $18.32.2. Tivity Health (TVTY)
13.3% sales growth and 175.22% return on equity
Tivity Health, Inc. offers fitness, nutrition, social connections solutions throughout the United States.
Tivity Health's sales growth this year is anticipated to be 16.2% and 11.2% for next year.
Year-on-year quarterly revenue growth grew by 26%, now sitting on 481.25M for the twelve trailing months.
Volume
Today's last reported volume for Tivity Health is 1199250 which is 79.96% above its average volume of 666381.
Tivity Health's sales growth for the next quarter is 13.3%. The company's growth estimates for the present quarter and the next is 2.5% and negative -8.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 175.22%.
Volatility
Tivity Health's last day, last week, and last month's current intraday variation average was 0.09%, 0.34%, and 0.94%, respectively.
Tivity Health's highest amplitude of average volatility was 0.53% (day), 1.60% (last week), and 2.38% (last month), respectively.
Tivity Health's Stock Yearly Top and Bottom Value
Tivity Health's stock is valued at $32.27 at 11:23 EST, below its 52-week high of $32.89 and way above its 52-week low of $21.25.
Tivity Health's Moving Average
Tivity Health's worth is way above its 50-day moving average of $28.40 and way above its 200-day moving average of $25.62.3. Supernus Pharmaceuticals (SUPN)
9.4% sales growth and 10.76% return on equity
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on developing and marketing products to treat central nervous system disorders in the United States.
Supernus Pharmaceuticals's sales growth this year is anticipated to be 8.9% and 19% for next year.
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 564.28M for the twelve trailing months.
Volume
Today's last reported volume for Supernus Pharmaceuticals is 287190 which is 33.96% below its average volume of 434886.
Supernus Pharmaceuticals's sales growth for the next quarter is 9.4%. The company's growth estimates for the current quarter and the next is a negative 50.9% and 236.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.76%.
Volatility
Supernus Pharmaceuticals's last day, last week, and last month's current intraday variation average was 0.91%, 0.73%, and 1.05%, respectively.
Supernus Pharmaceuticals's highest amplitude of average volatility was 2.74% (day), 2.59% (last week), and 2.89% (last month), respectively.
Supernus Pharmaceuticals's Stock Yearly Top and Bottom Value
Supernus Pharmaceuticals's stock is valued at $32.38 at 11:23 EST, below its 52-week high of $34.50 and way above its 52-week low of $23.15.
Supernus Pharmaceuticals's Moving Average
Supernus Pharmaceuticals's worth is above its 50-day moving average of $31.03 and way higher than its 200-day moving average of $29.41.4. SS&C Technologies Holdings (SSNC)
8.6% sales growth and 13.21% return on equity
Together with its subsidiaries, SS&C Technologies Holdings, Inc. provides software products as well as software-enabled service to the financial and healthcare sectors.
SS&C Technologies Holdings's sales growth this year is anticipated to be 7.2% and 3.9% for next year.
Year-on-year quarterly revenue growth grew by 9.7%, now sitting on 4.96B for the twelve trailing months.
Volume
Today's last reported volume for SS&C Technologies Holdings is 857904 which is 29.99% below its average volume of 1225550.
SS&C Technologies Holdings's sales growth for the next quarter is 8.6%. The company's growth estimates for the ongoing quarter and the next is 8.8% and 7.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.21%.
Volatility
SS&C Technologies Holdings's last day, last week, and last month's current intraday variation average was 0.25%, 2.06%, and 1.64%, respectively.
SS&C Technologies Holdings's highest amplitude of average volatility was 1.80% (day), 3.06% (last week), and 2.58% (last month), respectively.
SS&C Technologies Holdings's Stock Yearly Top and Bottom Value
SS&C Technologies Holdings's stock is valued at $71.08 at 11:23 EST, way below its 52-week high of $84.85 and higher than its 52-week low of $68.15.